Shadow AI in Medical Content Workflows: Why Policy Alone Is Not Enough

A Digital or IT leader can publish a clear AI policy and still have no reliable view of how AI is being used in daily medical content work.

A team member may use an unapproved service to translate a draft, summarize a source, rework a slide, or compare document versions. The objective is usually practical: finish a legitimate task under time pressure. But the organization may lose visibility into the material, version, output process, and subsequent review.

That is the operational problem behind Shadow AI.

The durable response to Shadow AI is to replace an unsafe shortcut with an approved workflow that is easier to use and easier to govern.

Shadow AI describes a control gap—not a confirmed breach

Shadow AI is the use of an AI system for work without the organization's approval, visibility, or required controls.

Unsanctioned use does not automatically prove that confidential information was disclosed, that a vendor trained on the data, or that a compliance violation occurred. Those conclusions depend on the material, service, account, terms, configuration, retention, access controls, jurisdiction, and intended use.

The problem is that the organization may not have the evidence needed to answer those questions.

The same AI product could be used through an approved enterprise environment or a personal account outside organizational oversight. Governance must follow the actual context of use, not a product label alone.

The demand for AI will not wait for the policy

A 2024 Microsoft and LinkedIn Work Trend Index survey found that 78% of surveyed AI users were bringing their own AI tools to work. This was a cross-industry workforce finding, not a pharmaceutical-industry adoption rate. It nevertheless illustrates a broad organizational challenge: when employees see immediate utility and the approved route is absent, unclear, or cumbersome, use can move outside formal systems.

A 2026 Pharma Sessions episode with Emily Lewis, AI and Innovation Lead at UCB, similarly focused on AI literacy, governance, and regulatory workflows in life sciences. The practical implication is not that every team should adopt every AI use case. It is that organizations need an intentional path for evaluating and governing the work people are already trying to perform.

A blanket prohibition may be appropriate for certain data classes or high-risk decisions. But it does not remove the underlying jobs: translation, version comparison, evidence retrieval, drafting, and preparation for formal MLR review.

If the sanctioned workflow cannot meet that need, another shortcut may appear—even after one tool is blocked.

How Shadow AI changes medical content risk

Medical content materials carry several layers of context: claims, evidence, intended audience, market, product status, approved language, source versions, review history, and decision ownership. When work moves into an ungoverned AI interaction, some of that context can disappear.

The risk is not simply that an AI output may be wrong. It is that the workflow may become difficult to reconstruct. A correct-looking sentence can still be based on the wrong source version, omit a limitation, or pass into later drafts without a clear review record.

Five control layers for a sanctioned AI path

An effective response should combine policy and technical safeguards with a workflow people can realistically use.

1. Define the authorized route

Specify which services, accounts, environments, integrations, and use cases are approved. Also establish a request path for new use cases. Otherwise, legitimate needs remain invisible until they appear as exceptions.

2. Set the input boundary

Define what may and may not enter each system. Relevant distinctions may include public content, internal content, confidential business information, personal data, patient-related information, unpublished evidence, and controlled source material.

For each permitted class, teams should understand retention, access, residency, reuse, de-identification, and deletion conditions. No single label replaces deployment-specific review.

3. Limit the task and decision authority

Approval should attach to a defined context of use, not to "AI" in general.

A tool approved to draft a translation is not automatically approved to determine whether the localized claim is acceptable. A system allowed to flag a possible evidence mismatch is not automatically allowed to approve the material or block distribution.

State what the system may assist, what its output means, what action it can trigger, and which decisions remain with qualified people.

4. Preserve traceability

For material outputs, teams may need to reconstruct:

• which material and version entered the workflow;
• which source, approved claim, SOP, or rule was used;
• which system and configuration produced the output;
• what the system flagged or generated;
• who reviewed, changed, accepted, or rejected it; and
• which version moved forward.

Documentation should be proportionate to the task and risk, preserving the evidence required for governed decisions.

5. Keep human ownership operational

Human oversight must be more than a policy sentence.

Qualified reviewers need access to the material, evidence, uncertainty, and rationale. They must be able to override, document a reason, escalate, and stop the workflow when evidence is insufficient.

The vendor remains responsible for the security, contractual commitments, and documented behavior of its product. The deploying organization remains responsible for approving the context of use, configuring the workflow, training users, and assigning downstream decision rights. Governance fails when either side is treated as having no responsibility.

A practical response: discover, classify, replace, monitor, improve

The first step is not to hunt for individual rule-breakers. It is to identify the jobs moving outside approved systems.

Discover the task demand

Map where teams use or want AI, the material involved, the affected decision, and the current workaround.

Classify the risk

Assess data sensitivity, regulatory relevance, decision impact, error detectability, and whether a later human check can realistically catch a problem.

Replace the shortcut

Provide an approved route that makes permitted inputs, supported actions, limitations, and review requirements visible. If it adds too much friction, adoption will remain fragile.

Monitor the workflow

Use proportionate logging, access review, exception reporting, and incident routing to test whether controls work.

Improve the path

Review exceptions, friction, rework, and recurring risks. Then update training, integrations, source access, rules, or tool scope through change control.

This approach treats Shadow AI as both a risk and a design signal. It contains unsafe use while learning what the organization needs to support.

Questions for Digital, IT, and AI governance teams

Before approving an AI-assisted medical content workflow, ask:

1. What exact user job and material type are in scope?
2. Which data classes are permitted, restricted, or prohibited?
3. Where is information processed, retained, accessed, and deleted?
4. Can provider terms, settings, or model changes alter those conditions?
5. Which controlled sources and versions support the output?
6. What must a qualified reviewer verify before the output is used?
7. Can the organization reconstruct the material, evidence, system version, and human decision?
8. How will exceptions, suspected incidents, and new use-case requests be handled?

These questions should be reviewed with the appropriate Information Security, Privacy, Legal, Quality, Compliance, Medical, and workflow owners for the deployment in question.

Where ZENO fits

ZENO is designed as a governed MLR pre-review layer for medical content materials before formal MLR approval.

It helps teams identify and locate potential review risks, connect findings to source evidence and company-specific review logic, explain why an issue was flagged, and route uncertain or material questions to qualified reviewers.

ZENO is not a replacement for enterprise identity management, data-loss prevention, privacy governance, records management, or acceptable-use controls. Its role is narrower: provide a task-specific, human-supervised review path where medical content teams can inspect potential risks before the material enters formal MLR approval.

Shadow AI cannot be solved by telling people to stop needing help. The safer path has to be governed—and useful enough to become the path people choose.